Drug Profile
JNJ 61178104
Alternative Names: JNJ-61178104Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Janssen Research & Development
- Class
- Mechanism of Action Inflammation mediator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 05 Sep 2023 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in Belgium (IV) (Janssen Research & Development pipeline, September 2023)
- 05 Sep 2023 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in Belgium (SC) (Janssen Research & Development pipeline, September 2023)
- 05 Sep 2023 Discontinued - Preclinical for Autoimmune disorders in USA (Parenteral) (Janssen Research & Development pipeline, September 2023)